PIM
ALNY icon

Plato Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Plato Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Sell
3,671
-2,578
-41% -$778K 0.06% 261
2026
Q1 		$2.07M Sell
6,249
-5
-0.1% -$1.7K 0.14% 156
2025
Q4 		$2.5M Buy
6,254
+1,348
+27% +$597K 0.16% 130
2025
Q3 		$2.22M Buy
4,906
+793
+19% +$323K 0.15% 142
2025
Q2 		$1.34M Sell
4,113
-546
-12% -$151K 0.1% 211
2025
Q1 		$1.27M Sell
4,659
-888
-16% -$228K 0.11% 212
2024
Q4 		$1.31M Buy
5,547
+845
+18% +$222K 0.1% 225
2024
Q3 		$1.29M Buy
4,702
+1,173
+33% +$305K 0.1% 204
2024
Q2 		$858K Sell
3,529
-980
-22% -$155K 0.08% 225
2024
Q1 		$674K Buy
4,509
+4,346
+2,666% +$725K 0.07% 240
2023
Q4 		$31.2K Buy
+163
New +$27.8K 0.04% 277

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Plato Investment Management's ALNY Position: Q2 2026 in Review

Plato Investment Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 41% in Q2 2026, selling an estimated $778K and leaving 3,671 shares worth $1.1M. The position accounts for 0.06% of the portfolio, ranked #261.

Plato Investment Management first reported a position in ALNY in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.5M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Plato Investment Management held 3,671 shares of Alnylam Pharmaceuticals worth $1.1M as of Q2 2026.
  • Plato Investment Management sold 2,578 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $778K.
  • Alnylam Pharmaceuticals made up 0.06% of Plato Investment Management's portfolio in Q2 2026, its #261 holding.
  • Plato Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Plato Investment Management's Alnylam Pharmaceuticals position peaked at $2.5M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Plato Investment Management's 13F filing for Q2 2026, filed 7 Aug 2026.